Home > Formulary : Adult > Chapters > 7. Obstetrics, Gynaecology and Urinary-tract Disorders >
BNSSG Adult Joint Formulary
7.6 Vaginal and vulval conditions
Last edited: 24-10-2024
7.6.1 Vaginal and vulval infections, bacterial
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
Clindamycin cream (TLS Green)
Metronidazole 0.75% gel (TLS Green)
Dequalinium chloride (Fluomizin® 10mg vaginal tablets) (TLS Amber Specialist Recommended)
- For treatment of bacterial vaginosis
Dequalinium chloride (Fluomizin® 10mg vaginal tablets) (TLS Red)
- For treatment of trichomoniasis vaginalis
7.6.2 Vaginal and vulval infections, fungal
Clotrimazole 1% cream (TLS Green)
Clotrimazole pessary 500mg (TLS Green)
7.6.3 Vaginal atrophy
Yes! vaginal moisturiser (TLS Green)
- For vaginal atrophy in post-menopausal women with oestrogen sensitive conditions for whom topical oestrogens are not suitable i.e. patients with a history of breast or endometrial cancer
- Use nightly until see a benefit and then twice weekly
Estriol cream 0.1% (TLS Green)
Estradiol vaginal tablets 10micrograms (TLS Green) (local use)
Estring® Vaginal Ring (TLS Blue)
Imvaggis® Pessary (TLS Blue)
- 2nd line after vaginal moisturisers for women with oestrogen-sensitive conditions following discussion with oncologist or menopause specialist
- 4th line for women who have not tolerated other formulary options
Ospemifene® tablets (TLS Amber Specialist Recommended)
For moderate to severe vulvovaginal atrophy in women who have:
- History of breast cancer for whom low dose estriol (Imvaggis®pessary) is unsuitable or;
- A significant local allergy to vaginal oestrogens or;
- For those who have failed to respond to all other formulary options after several months of treatment
Prasterone (DHEA) gel (TLS Red)
- Reserved for postmenopausal women who are taking an aromatase inhibitor
- Or as a last line option for women who are intolerant to all other formulary options for VVA due to allergy or issues with absorption.
Contact Us
Got a question or comment about the Joint Formulary?
Please use the email address below to contact us and we will endeavour to respond within 2 working days.